BFA
IBRX icon

BlackRock Fund Advisors’s ImmunityBio IBRX Stock Holding History

BlackRock Fund Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9.58M Buy
1,674,508
+141,805
+9% +$946K ﹤0.01% 2597
2016
Q3 		$11.9M Buy
1,532,703
+83,295
+6% +$622K ﹤0.01% 2361
2016
Q2 		$9.02M Buy
1,449,408
+226,513
+19% +$1.76M ﹤0.01% 2466
2016
Q1 		$10.1M Buy
1,222,895
+115,958
+10% +$1.09M ﹤0.01% 2341
2015
Q4 		$19.2M Buy
1,106,937
+948,237
+598% +$14.1M ﹤0.01% 2068
2015
Q3 		$1.82M Buy
+158,700
New +$3.46M ﹤0.01% 3136

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Fund Advisors's IBRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its ImmunityBio (IBRX) stake by 9.3% in Q4 2016, buying an estimated $946K and bringing the position to 1,674,508 shares worth $9.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2597.

BlackRock Fund Advisors first reported a position in IBRX in Q3 2015 and has held it in 6 quarters since. The position peaked at $19.2M in Q4 2015. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

  • BlackRock Fund Advisors held 1,674,508 shares of ImmunityBio worth $9.58M as of Q4 2016.
  • BlackRock Fund Advisors bought 141,805 ImmunityBio shares in Q4 2016, an estimated $946K.
  • ImmunityBio made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2597 holding.
  • BlackRock Fund Advisors first reported a position in ImmunityBio in Q3 2015 and has held it in 6 quarters since.
  • BlackRock Fund Advisors's ImmunityBio position peaked at $19.2M in Q4 2015.
  • 68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.